Infertility Drugs Market (By Drug Class: Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, Others; By Distribution Channel: Hospital Pharmacy, Specialty & Retail Pharmacy, Online Pharmacy; By End-user: Men, Women) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global infertility drugs market size was valued at USD 3.71 billion in 2023 and is predicted to reach around USD 6.73 billion by 2033, growing at a CAGR of 6.13% from 2024 to 2033. The primary reasons behind the growth of this market are developments in healthcare facilities and a desire for parenthood among married couples.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. infertility drugs market size reached USD 1.16 billion in 2023 and is predicted to be worth around USD 2.11 billion by 2033, at a CAGR of 6.16% from 2024 to 2033.
North America dominated the infertility drugs market in 2023. The biggest reason why we see a large sale of infertility drugs in North America is that the lifestyle followed by North American people is extremely unhealthy. Due to a high amount of sugary and salty foods, there is a rise in obesity and eating disorders, which hampers sperm quality or leads to poor reproductive health in females. Another main issue is the habit of smoking. Recent reports say that one in five deaths in the U.S. happens because of smoking. Smoking can hamper sperm quality, making them weak and reducing their mobility.
Asia Pacific will have the fastest growth rate in the global infertility drugs market during the forecast period. Infertility is rising in Asia Pacific because of several factors. People are choosing to marry late while focusing on their careers in countries like India. A trend has been seen that people with higher education levels and late marriages show primary infertility. Apart from this, smoking, tobacco consumption, obesity, and other diseases show their link with secondary infertility. Several awareness programs have been conducted, and people have become alert about their reproductive health because of this.
The Asia Pacific infertility drugs market size was calculated at USD 1.04 billion in 2023 and is estimated to cross around USD 1.92 billion by 2033 with a notable CAGR of 6.32% from 2024 to 2033.
Year | Market Size (USD Billion) |
2023 | 1.04 |
2024 | 1.10 |
2025 | 1.17 |
2026 | 1.24 |
2027 | 1.32 |
2028 | 1.40 |
2029 | 1.48 |
2030 | 1.58 |
2031 | 1.67 |
2032 | 1.78 |
2033 | 1.92 |
Infertility is a condition of not being able to achieve pregnancy after 12 months or more of regular unprotected sex. Infertility is divided into primary and secondary infertility. Primary infertility is when parents are unable to conceive for the first child, and secondary infertility is when parents are unable to conceive for the second child. Infertility issues can be in men and women as well. Sometimes, there can be an issue with both partners and sometimes, it can be totally unexplained. There are many reasons behind infertility, and it mainly depends upon the lifestyle of both partners. If the partners have addictions like smoking, drinking, or obesity due to bad food habits, this can affect reproductive fitness adversely and can lead to impotence in males and the inability to conceive in females.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 6.13% |
Global Market Size in 2023 | USD 3.71 Billion |
Global Market Size in 2024 | USD 3.94 Billion |
Global Market Size by 2033 | USD 6.73 Billion |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Drug Class, By Distribution Channel, and By End-user |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Drivers: Bad lifestyle
Due to bad habits and addictions, an increasing population is getting infertile. Smoking has become a new trend. Many corporate employees and students catch a habit of smoking in their life at some stage and become addicted to it. However, smoking and alcoholism can have severe effects on the reproductive system of males as well as females. In males, such bad habits can lead to impotence or erectile dysfunction, and in females, it can lead to an inability to conceive. Awareness is being spread regarding infertility issues through advertisements and even movies that talk about infertility.
Restraint: Awareness issues and side effects
Infertility is a subject that is thought to be taboo and shameful in many villages. It is thought to be shameful not being able to conceive. In many Indian villages, due to a lack of education, women are thought to be solely responsible for not being able to conceive. There is an importance of awareness in these areas. Infertility drugs of high quality should be made aware in government hospitals, and awareness should be spread, too. Infertility drugs, however, are expensive and are not affordable for many people. There is also a stigma in society when someone consumes such drugs, and people are hesitant when it comes to getting treatment for infertility. Infertility drugs need proper testing and approval processes, which can take a long time. Also, testing them on subjects can cause problems with their health. Infertility drugs can have potential side effects, too; for example, the child might have poor immunity and health issues in the future.
Opportunities: Another reproductive health market
The infertility drugs market will open opportunities for several other markets like childcare, IVF, etc. There will be a growth in healthcare infrastructure, and more awareness about infertility will spread. Due to more advancements in technology, people can produce healthy babies. The infertility drugs market will also boost the surrogacy market and infertility tourism. Parents can travel to different countries to get effective treatments for infertility. More awareness about infertility in rural areas as well as urban areas will help fight the stigma that people have regarding infertility.
According to the drug class, the gonadotropins segment dominated the infertility drugs market in 2023 and is expected to continue this dominance throughout the forecast period. It will achieve the highest growth during the forecast period. Gonadotropins are high in cost and are used widely. Gonadotropins are naturally produced by the pituitary glands and stimulate the ovaries to produce a ‘follicle’ containing an egg, which then releases the egg from the ovary. For those who are not able to ovulate, gonadotropins are given to stimulate ovulation. Gonadotropin helps those who are ovulating but are facing problems in conceiving. Gonadotropins for medical purposes are produced in the laboratory and injected under the skin to be effective. It is generally given to women who do not have regular menstrual periods and have very low levels of LH and FSH hormones.
According to the drug class, the selective estrogen receptor modulators segment is predicted to show rapid growth in the infertility drugs market. SERMs are used for indcing ovulation in women having ovulation disorders. SERMs can stimulate ovulation and hence improve the chances of getting pregnant. Some SERMs also find uses in breast cancer treatment, and this, too, helps grow the market. For example, tamoxifen is a drug that can induce ovulation and can also stop the activity of estrogen in the breasts.
According to the distribution channel, the hospital pharmacy segment dominated the infertility drugs market in 2023. This is because people prefer to have a proper consultation and treatment with highly qualified professional doctors and then take the medicines. This channel is more popular because patients can get physically diagnosed by the doctors and continue the consultation, visit clinics for regular checkups, and there is a sense of assurance and security in a couple’s mind.
In the infertility drugs market, the online pharmacy segment is expected to grow at a high rate over the forecast period. Ordering online is accessible and convenient. Online medicine delivery has become convenient, and people who don’t have access to shops nearby or live in remote areas can consult doctors online and order medicines. Privacy is assured when ordering online, as many people find it to be embarrassing due to social pressures and stigma. There is also a wider variety of medications available online. Online websites also provide discounts. People can get effective customer support when ordering online.
By end-user, the women segment dominated the infertility drugs market in 2023. It has been found that women show higher depression levels than men when it comes to infertility. This is mainly because of the social stigma and a lack of knowledge in the orthodox families. Studies have also shown that a failure in one treatment shows a higher level of distress in women when taking treatment next time. In some societies, women are considered to be solely responsible for the infertility issues. Infertility issues in women can be complex. There can be issues with ovulation, blockages in the fallopian tubes, or other abnormalities in the uterus. Women are also more aware of their reproductive health.
In the infertility drugs market, the men segment will be the fastest-growing segment during the forecast period. There is a growing awareness of male infertility. Many males are working professionals and catch bad habits and addictions like smoking or drinking. This often leads to a low sperm count, a fall in sperm motility, sperm deformation, or impotence. Men also take infertility treatment to accompany their spouses, as couples have become aware that the problem might lie with either of them. Regular checkups are done in order to check if there are any other health issues like genetic factors or hormonal issues.
Segments Covered in the Report
By Drug Class
By Distribution Channel
By End-user
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Infertility Drugs Market
5.1. COVID-19 Landscape: Infertility Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Infertility Drugs Market, By Drug Class
8.1. Infertility Drugs Market Revenue and Volume, by Drug Class, 2024-2033
8.1.1 Gonadotropins
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Aromatase Inhibitors
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Selective Estrogen Receptor Modulators (SERMs)
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Dopamine Agonists
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Infertility Drugs Market, By Distribution Channel
9.1. Infertility Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Specialty & Retail Pharmacy
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Infertility Drugs Market, By End-user
10.1. Infertility Drugs Market Revenue and Volume, by End-user, 2024-2033
10.1.1. Men
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Women
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Infertility Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End-user (2021-2033)
Chapter 12. Company Profiles
12.1. Merck & Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Ferring B.V.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Organon Group of Companies
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Abbott
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mankind Pharma
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Teva Pharmaceutical Industries LTD.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client